At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02142 HBM HOLDINGS-B
Market Closed 01-09 16:08:35
14.000
-0.120
-0.85%
High14.320Low13.780Vol3.51M
Open14.290D1 Closing14.120Amplitude3.82%
Mkt Cap12.15BTradable Cap12.15BTotal Shares868.00M
T/O49.28MT/O Rate0.40%Tradable Shares868.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Undiscovered Gems in Asia To Explore This January 2026
Simply Wall St.  ·  01-09 12:03
Undiscovered Gems in Asia To Explore This January 2026
HBM HOLDINGS-B (02142) Rises Over 3% as Jointly Submitted Pancreatic Cancer Research Project with Changhai Hospital Gains Major National Science and Technology Innovation Grant
Stock News  ·  01-07
HBM HOLDINGS-B (02142) Rises Over 3% as Jointly Submitted Pancreatic Cancer Research Project with Changhai Hospital Gains Major National Science and Technology Innovation Grant
CICC Maintains Outperform Rating on HBM HOLDINGS-B (02142), Raises Target Price to HK$18
Stock News  ·  01-07
CICC Maintains Outperform Rating on HBM HOLDINGS-B (02142), Raises Target Price to HK$18
HBM Holdings Files Next Day Disclosure to HKEX After Repurchasing 100,000 Shares for HKD 1.22 Million
Reuters  ·  01-02
HBM Holdings Files Next Day Disclosure to HKEX After Repurchasing 100,000 Shares for HKD 1.22 Million
HBM HOLDINGS-B (02142) Grants 309,000 Share Options
Stock News  ·  01-01
HBM HOLDINGS-B (02142) Grants 309,000 Share Options
HBM Holdings Grants Share Options to Employee Under Existing Scheme
Reuters  ·  01-01
HBM Holdings Grants Share Options to Employee Under Existing Scheme
Zhixiang Hong Kong Stock Repurchase Statistics | January 1
Stock News  ·  01-01
Zhixiang Hong Kong Stock Repurchase Statistics | January 1
HBM Holdings Files HKEX Disclosure on Repurchase of 100,000 Shares for HKD 1.22 Million
Reuters  ·  2025-12-31
HBM Holdings Files HKEX Disclosure on Repurchase of 100,000 Shares for HKD 1.22 Million
HBM HOLDINGS-B (02142) Repurchases 300,000 Shares for HK$3.6305 Million on December 30
Stock News  ·  2025-12-30
HBM HOLDINGS-B (02142) Repurchases 300,000 Shares for HK$3.6305 Million on December 30
Harbour BioMed and Lannacheng Launch Strategic Collaboration on Next-Generation Radionuclide Drug Conjugates
Reuters  ·  2025-12-29
Harbour BioMed and Lannacheng Launch Strategic Collaboration on Next-Generation Radionuclide Drug Conjugates
Harbour Biomed Enters Into Long-Term Strategic Collaboration With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
THOMSON REUTERS  ·  2025-12-29
Harbour Biomed Enters Into Long-Term Strategic Collaboration With Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects
Simply Wall St.  ·  2025-12-20
HBM Holdings (SEHK:2142): Valuation Check After Bristol Myers Squibb Collaboration Validates Growth Prospects
HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
Stock News  ·  2025-12-19
HK Stock Movement | HBM Holdings-B (02142) Surges Over 8% in Early Trading on $1B+ BD Deal with Bristol-Myers Squibb
HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
Stock News  ·  2025-12-17
HK Stock Movement | HBM HOLDINGS-B (02142) Still Down 2% After Signing Global Strategic Collaboration with Bristol-Myers Squibb, Potential Earnings Exceed $1 Billion
Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
Reuters  ·  2025-12-17
Hbm Holdings Enters Global Strategic Collaboration And License Agreement With Bristol Myers Squibb
HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
Reuters  ·  2025-12-17
HBM Holdings and Bristol Myers Squibb Sign Global Strategic Collaboration Agreement
Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
THOMSON REUTERS  ·  2025-12-17
Hbm Holdings - Entering Into Global Strategic Collaboration and License Agreement With Bristol Myers Squibb
Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
THOMSON REUTERS  ·  2025-12-17
Hbm Holdings - Under Deal, Co to Collaborate to Advance and Accelerate Multi-Specific Antibody Discovery Programs
Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
THOMSON REUTERS  ·  2025-12-17
Hbm Holdings - Could Receive Payments Totaling $90 Mln & Development and Commercial Milestones of up to $1,035 Mln Under Deal
Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?
Simply Wall St.  ·  2025-12-17
Declining Stock and Solid Fundamentals: Is The Market Wrong About HBM Holdings Limited (HKG:2142)?

Introduction

Company Name.
HBM HOLDINGS-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Hbm Holdings Ltd is an investment holding company primarily engaged in the business of developing innovative therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products primarily include BATOCLIMAB (HBM9161), HBM9378, HBM7020, TCE Program, PORUSTOBART (HBM4003), HBM7022 and others. The products are primarily used to treat generalized myasthenia gravis (gMG), chronic obstructive pulmonary disease (COPD), asthma, autoimmune diseases, melanoma, colorectal carcinoma (CRC) and solid tumors. The Company provides next-generation antibody and biotherapeutic solutions through proprietary antibody technology platforms including Harbour Mice, HBICE, HBICA and single B cell cloning platform.
Issue price:
--